QQQ   293.41 (-0.41%)
AAPL   141.83 (-1.70%)
MSFT   246.96 (-0.34%)
META   148.88 (-0.06%)
GOOGL   98.04 (-0.81%)
AMZN   101.88 (-1.21%)
TSLA   172.72 (-0.29%)
NVDA   199.99 (+2.36%)
NIO   11.69 (-3.15%)
BABA   110.78 (+0.53%)
AMD   81.11 (+7.93%)
T   20.33 (-0.20%)
MU   61.23 (+1.54%)
F   13.60 (+0.67%)
CGC   2.97 (-1.98%)
GE   81.08 (+0.75%)
DIS   107.89 (-0.55%)
AMC   5.34 (-0.19%)
PFE   43.85 (-0.70%)
PYPL   80.64 (-1.04%)
NFLX   356.14 (+0.64%)
QQQ   293.41 (-0.41%)
AAPL   141.83 (-1.70%)
MSFT   246.96 (-0.34%)
META   148.88 (-0.06%)
GOOGL   98.04 (-0.81%)
AMZN   101.88 (-1.21%)
TSLA   172.72 (-0.29%)
NVDA   199.99 (+2.36%)
NIO   11.69 (-3.15%)
BABA   110.78 (+0.53%)
AMD   81.11 (+7.93%)
T   20.33 (-0.20%)
MU   61.23 (+1.54%)
F   13.60 (+0.67%)
CGC   2.97 (-1.98%)
GE   81.08 (+0.75%)
DIS   107.89 (-0.55%)
AMC   5.34 (-0.19%)
PFE   43.85 (-0.70%)
PYPL   80.64 (-1.04%)
NFLX   356.14 (+0.64%)
QQQ   293.41 (-0.41%)
AAPL   141.83 (-1.70%)
MSFT   246.96 (-0.34%)
META   148.88 (-0.06%)
GOOGL   98.04 (-0.81%)
AMZN   101.88 (-1.21%)
TSLA   172.72 (-0.29%)
NVDA   199.99 (+2.36%)
NIO   11.69 (-3.15%)
BABA   110.78 (+0.53%)
AMD   81.11 (+7.93%)
T   20.33 (-0.20%)
MU   61.23 (+1.54%)
F   13.60 (+0.67%)
CGC   2.97 (-1.98%)
GE   81.08 (+0.75%)
DIS   107.89 (-0.55%)
AMC   5.34 (-0.19%)
PFE   43.85 (-0.70%)
PYPL   80.64 (-1.04%)
NFLX   356.14 (+0.64%)
QQQ   293.41 (-0.41%)
AAPL   141.83 (-1.70%)
MSFT   246.96 (-0.34%)
META   148.88 (-0.06%)
GOOGL   98.04 (-0.81%)
AMZN   101.88 (-1.21%)
TSLA   172.72 (-0.29%)
NVDA   199.99 (+2.36%)
NIO   11.69 (-3.15%)
BABA   110.78 (+0.53%)
AMD   81.11 (+7.93%)
T   20.33 (-0.20%)
MU   61.23 (+1.54%)
F   13.60 (+0.67%)
CGC   2.97 (-1.98%)
GE   81.08 (+0.75%)
DIS   107.89 (-0.55%)
AMC   5.34 (-0.19%)
PFE   43.85 (-0.70%)
PYPL   80.64 (-1.04%)
NFLX   356.14 (+0.64%)
NASDAQ:CCXI

ChemoCentryx - CCXI Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$51.99
$51.99
50-Day Range
$51.66
$51.99
52-Week Range
$14.95
$52.00
Volume
113 shs
Average Volume
1.68 million shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.40

ChemoCentryx MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
23.9% Upside
$64.40 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.81) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

953rd out of 1,053 stocks

Pharmaceutical Preparations Industry

465th out of 519 stocks


CCXI stock logo

About ChemoCentryx (NASDAQ:CCXI) Stock

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Stock News Headlines

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
ChemoCentryx (NASDAQ: CCXI)
Biotech Valuations Remain In a Slump - TheStreet
See More Headlines

Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Company Calendar

Last Earnings
11/08/2021
Today
2/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CCXI
CUSIP
16383L10
Employees
178
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$64.40
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$52.00
Forecasted Upside/Downside
+23.9%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-131,760,000.00
Net Margins
-357.01%
Pretax Margin
-357.01%

Debt

Sales & Book Value

Annual Sales
$32.22 million
Book Value
$4.09 per share

Miscellaneous

Free Float
65,433,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
1.22

Key Executives

  • Dr. Thomas J. Schall Ph.D. (Age 63)
    Founder, Pres, CEO & Chairman
    Comp: $1.21M
  • Ms. Susan M. Kanaya (Age 59)
    Exec. VP, Chief Financial & Admin. Officer, Sec. and Director
    Comp: $845.04k
  • Mr. Tausif  ButtMr. Tausif Butt (Age 56)
    Exec. VP & COO
    Comp: $1.01M
  • Dr. Rita I. Jain M.D. (Age 59)
    Exec. VP, Chief Medical Officer & Exec. Employee Director
    Comp: $670.7k
  • Dr. Markus J. Cappel Ph.D. (Age 61)
    Chief Bus. Officer & Treasurer
    Comp: $643.58k
  • Ms. Yi Ching Yau (Age 46)
    Sr. VP of Fin. & Principal Accounting Officer
  • Mr. William S. Slattery
    VP of Investor Relations & Corp. Communications
  • Ms. Kari E. Leetch
    Sr. VP of HR
  • Dr. Sangita Ghosh Ph.D.
    Sr. VP of Technical Operations













CCXI Stock - Frequently Asked Questions

Should I buy or sell ChemoCentryx stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CCXI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCXI, but not buy additional shares or sell existing shares.
View CCXI analyst ratings
or view top-rated stocks.

What is ChemoCentryx's stock price forecast for 2023?

5 Wall Street analysts have issued 1-year target prices for ChemoCentryx's stock. Their CCXI share price forecasts range from $52.00 to $85.00. On average, they anticipate the company's stock price to reach $64.40 in the next year. This suggests a possible upside of 23.9% from the stock's current price.
View analysts price targets for CCXI
or view top-rated stocks among Wall Street analysts.

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) released its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.13. The biopharmaceutical company earned $17.74 million during the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative net margin of 357.01% and a negative trailing twelve-month return on equity of 48.52%. During the same period in the prior year, the company earned ($0.35) EPS.

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

21 employees have rated ChemoCentryx Chief Executive Officer Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among the company's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 44.0% of employees surveyed would recommend working at ChemoCentryx to a friend.

What other stocks do shareholders of ChemoCentryx own?
What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by many different institutional and retail investors. Top institutional investors include Equitec Proprietary Markets LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends
.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $51.99.

How much money does ChemoCentryx make?

ChemoCentryx (NASDAQ:CCXI) has a market capitalization of $3.71 billion and generates $32.22 million in revenue each year. The biopharmaceutical company earns $-131,760,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How many employees does ChemoCentryx have?

The company employs 178 workers across the globe.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The official website for the company is www.chemocentryx.com. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at investor@chemocentryx.com, or via fax at 650-210-2910.

This page (NASDAQ:CCXI) was last updated on 2/1/2023 by MarketBeat.com Staff